BioFactura's Mission
BioFactura offers companies developing monoclonal antibody-based drugs shorter time-to-market, reduced costs, and high potency/fidelity drug candidates through the application of its proprietary Rapid Human Antibody Generation or RHAGe System. RHAGe is an end-to-end system for the discovery and commercialization of fully-human monoclonal antibody (mAb) drug candidates. The system integrates proprietary in-house and external discovery, development, and manufacturing technologies. Central to RHAGe is BioFactura’s VeriCyte Discovery Platform for the isolation of fully-human therapeutic mAbs from human B cells. The Company’s StableFast Biomanufacturing Platform allows the rapid development and production of lead mAb candidates.